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Abstract  
Corticosteroids (CSs) are widely used clinically, for example in paediatric respiratory 
distress syndrome, and immunosuppression to prevent rejection of stem cell 
transplant populations in neural cell therapy. However, such treatment can be 
associated with adverse effects such as impaired neurogenesis and myelination, and 
increased risk of cerebral palsy. There is increasing evidence that CSs can 
adversely influence key biological properties of neural stem cells (NSCs) but the 
molecular mechanisms underpinning such effects are largely unknown. This is an 
important issue to address given the key roles NSCs play during brain development 
and as transplant cells for regenerative neurology. Here, we describe the use of 
label-free quantitative proteomics in conjunction with histological analyses to study 
CS effects on NSCs at the cellular and molecular levels, following treatment with 
methylprednisolone (MPRED). Immunocytochemical staining showed that both 
parent NSCs and newly generated daughter cells expressed the glucocorticoid 
receptor, with nuclear localisation of the receptor induced by MPRED treatment. 
MPRED markedly decreased NSC proliferation and neuronal differentiation while 
accelerating the maturation of oligodendrocytes, without concomitant effects on cell 
viability and apoptosis. Parallel proteomic analysis revealed that MPRED induced 
downregulation of growth associated protein 43 and matrix metallopeptidase 16 with 
upregulation of the cytochrome P450 family 51 subfamily A member 1. Our findings 
support the hypothesis that some neurological deficits associated with CS use may 
be mediated via effects on NSCs, and highlight putative target mechanisms 
underpinning such effects. 
Keywords: Corticosteroid, neural stem cell, neural cell, proteomics 
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Abbreviations 
 
CS, corticosteroid; CNS, central nervous system; NSCs, neural stem cells; SCI, 
spinal cord injury; MPRED, methylprednisolone; NPCs, endogenous neural 
progenitor cells; FGF2, Human recombinant basic fibroblast growth factor; EGF, 
epidermal growth factor; TUJ 1, neuron specific class III β-tubulin; GFAP, glial 
fibrillary acidic protein; MBP, myelin basic protein; DAPI, 4′, 6-diamidino-2-
phenylindole; Ambic, Ammonium Bicarbonate; SVZ, subventricular zone; DMEM, 
Dulbecco’s Modified Eagle Medium; DMSO, dimethyl sulfoxide; PBS, phosphate 
buffered saline; PFA, paraformaldehyde; RT, room temperature; Edu, 5-ethynyl-2’-
deoxyuridine; FBS, fetal bovine serum; IPA, Ingenuity Pathway Analysis; GRs, 
glucocorticoid receptors; MMP-16, matrix metallopeptidase -16; GAP-43, growth 
associated protein 43; CYP51A1, cytochrome P450 family 51 subfamily A member 1; 
ECM, extracellular matrix; OPCs, oligodendrocyte precursor cells. 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
4 
 
1. Introduction 
Corticosteroids (CSs) are a group of small lipid-soluble molecules which readily pass 
through the blood-brain-barrier and exert physiological effects on the central nervous 
system (CNS) (Riedemann et al., 2010). Their responses are mediated by binding to 
a member of the nuclear receptor superfamily of transcription factors called 
glucocorticoid receptors (GRs) to form a cytoplasmic complex (Ayroldi et al., 2012; 
Rhen and Cidlowski, 2005). This complex migrates to the nucleus and binds directly 
to DNA sequences termed glucocorticoid response elements (GRE) in the promoter 
region, or other DNA bound transcription factors. This results in increased target 
gene expression such as for anti-inflammatory-proteins (transactivation), or reduced 
production of pro-inflammatory proteins (transrepression) (Rhen and Cidlowski, 
2005). 
The therapeutic effects of CSs as anti–inflammatory and immunosuppressive drugs 
have employed since the 1950s (Chari, 2014; Shinwell and Eventov-Friedman, 
2009) to treat diverse pathologies such as asthma, allergies and rheumatoid arthritis 
(Rhen and Cidlowski, 2005). In neural cell transplantation therapy, the use of anti-
inflammatory and immunosuppressive drugs such as CSs is essential to improve 
transplant survival and limit rejection by host tissue (Mazzini et al., 2015; Skardelly et 
al., 2013). Research has however highlighted several adverse effects of CSs, 
including elevated risks of neurodevelopmental impairment, cerebral palsy and 
cognitive impairment (Chari, 2014; Heine and Rowitch, 2009; Shinwell and Eventov-
Friedman, 2009). These risks are increased by prolonged and high exposure 
treatment, which can lead to structural changes in neurons and reduced 
neurogenesis, especially in the hippocampus, where inhibition of cell proliferation 
and increased cell death are observed in the dentate gyrus (Heberden et al., 2013).  
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Several in vivo and in vitro experimental studies suggest that at least some such 
adverse effects are mediated via effects on neural stem cells (NSCs) - self-renewing, 
multipotent cells that generate the major CNS cell types (astrocytes, neurons and 
oligodendrocytes). Extensive research shows that NSCs plays key roles in brain 
development and endogenous/transplant mediated repair (Skardelly et al., 2013). 
However, CS treatment can reduce NSC proliferation (a key underpinning of their 
regenerative effects) with aberrations in fetal and adult neurogenesis (Bose et 
al.,2010; Kim et al., 2004; Sundberg et al., 2006). Similarly, Bose et al. suggested 
that NSC exposure to CSs could reduce their proliferation without effects on 
survival/differentiation, whereas Moore and colleagues observed CS-mediated 
decreases in both the proliferation and differentiation of human NSCs (Bose et al., 
2010; Moors et al., 2012). Some studies have demonstrated that methylprednisolone 
(MPRED) can reduce endogenous neural progenitor cell proliferation in the spinal 
cord following traumatic SCI (Obermair et al., 2008).  
Given widespread clinical CS use, and the key roles of NSCs in developmental and 
regenerative processes, these findings highlight a significant need to investigate the 
mechanisms mediating CS effects on NSCs. Despite this, it should be noted that the 
overwhelming majority of studies investigating CS effects on NSCs rely exclusively 
on histological analyses. Whilst useful, such assays cannot provide detailed insight 
into the potential molecular mechanisms underpinning the observed neurological 
effects on NSCs. Here, we have adopted a dual methodological approach, 
employing parallel histological and proteomic analyses on CS-treated NSCs to 
address this issue. This allows us to generate independently validated and 
corroborative analyses of CS effects at both the morphological and molecular levels.  
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2. Materials and methods 
2.1. Reagents 
Cell culture reagents were from Life Technologies (Paisley, Scotland, UK) and 
Sigma-Aldrich (Poole, Dorset, UK). Nunc culture dishes (non-treated surface) and 
tissue culture-grade plastics were from Fisher Scientific (Loughborough, UK). Human 
recombinant basic fibroblast growth factor (FGF2) and epidermal growth factor 
(EGF) were from Sigma-Aldrich and R&D Systems Europe Ltd (Abingdon, UK), 
respectively. The following primary antibodies were used: Nestin (NSC specific 
marker; BD Biosciences, Oxford, UK), glial fibrillary acidic protein (GFAP – 
astrocytes; DakoCytomation, Ely, UK), neuron specific class III β-tubulin (TUJ 1- 
neurons; Covance, Princeton, NJ) and myelin basic protein (MBP – 
oligodendrocytes; Serotec, Kidlington, UK). Two glucocorticoid receptor antibodies 
H-300 and BuGR2 were from Santa Cruz Biotech (USA) and Abcam (UK), 
respectively. A neuronal marker rabbit anti- growth associated protein (GAP 43) was 
from (Abcam, UK). Secondary antibodies (Cy3- FITC-conjugated) were from 
Jackson Immunoresearch Laboratories Ltd (Westgrove, PA, USA). DAPI (4ʹ, 6-
diamidino-2-phenylindole) mounting medium was from Vector Laboratories 
(Peterborough, UK). 6-α-methylprednisolone (≥98% purity) was from Sigma. Click-
iT1 Edu Alexa Fluor kit was from Life Technologies, the LIVE/DEAD 
Viability/Cytotoxicity Assay Kit was from Invitrogen. Kits for cell cycle and Annexin V 
and Dead cell were from Millipore (Watford, UK). Trifluoroacetic acid was from Fisher 
Scientific. Acetonitrile was from VWR Chemicals (Lutterworth, UK), Iodoacetamide 
was from Acros Organics (Geel, Belgium) and Rapigest was from Waters 
Corporation (Altrincham, UK). Ammonium Bicarbonate (Ambic), protease inhibitor 
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cocktail, dithiothreitol, Proteomics-Grade dimethylated trypsin and Bradford Reagent 
were from Sigma.  
2.2. Isolation and culture of NSCs 
The care and use of all animals used in the production of cell cultures were in 
accordance with the Animals Scientific Procedures Act of 1986 (UK) with approval by 
the local ethics committee. 
NSCs were derived from the subventricular zone (SVZ) of CD1 mouse pups, post-
natal day 1-3 (the day of birth was designated as postnatal day 0) (Adams et al., 
2013). Briefly, under sterile conditions, sections containing SVZ were obtained. 
Tissue was mechanically dissociated into a single cell suspension in the presence of 
DNase I, cells were counted and plated at 1 x 105 cells/ml in neurosphere medium: 
3:1 mix Dulbecco’s Modified Eagle Medium (DMEM):F12 supplemented with 2% B27 
supplement, 20 ng/ml FGF2 and EGF, 4 ng/ml heparin, 50 U/ml penicillin, 50μg/ml 
streptomycin. Cultures were fed every 2-3 days and passaged every 5-7 days using 
a mix of accutase and DNase I. For adherent cultures, neurospheres were 
dissociated and plated on poly-L-ornithine and laminin coated coverslips and 
maintained in monolayer medium which was prepared with a 1:1 mix DMEM: F12, 
1% N2 supplement 20 ng/ml FGF-2 and EGF, 5 μg/ml heparin, 50 U/ml penicillin and 
50 μg/ml streptomycin. 
 
2.3. Preparation of MPRED solution 
The synthetic CS, MPRED is one of the main drugs used in the treatment of 
neurological trauma (acute SCI and traumatic brain injury) because of its ability to 
reduce brain edema, improve neurological recovery and reduce the inﬂammatory 
reaction after SCI (Han et al., 2014). This drug was therefore selected for use in 
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these experimental studies. MPRED stock was prepared in dimethyl 
sulfoxide (DMSO) with the concentration verified spectrophotometrically (Genesys 
10S UV−vis spectrophotometer, ThermoScientific, USA) then diluted in culture 
medium to the appropriate concentration. The highest dose of MPRED (10 μM) was 
used for further proteomic analysis.  
 
2.4. MPRED treatment of NSCs  
NSCs were cultured as adherent monolayers in 24-well plates at a density of 0.65 x 
105 cells/ ml (600 µl/well). One day after plating, NSCs were treated with MPRED by 
replacing cell culture medium with medium containing three different concentrations 
(0.1 μM, 1 μM and 10 μM) of MPRED followed by incubation for 48 h. The culture 
medium of untreated NSCs was replaced with fresh medium (without MPRED) and 
vehicle controls contained DMSO. Cells were then washed once in phosphate-
buffered saline (PBS), fixed with 4% paraformaldehyde (PFA), [15 mins, room 
temperature (RT)], before washing a further 3X in PBS, unless detailed otherwise. 
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2.5. NSC proliferation assay 
The 5-ethynyl-2’-deoxyuridine (Edu) assay was used to measure the effects of 
MPRED on cellular proliferation rates. Detection of Edu incorporation into the DNA 
was performed with Click-iT1 Edu Alexa Fluor proliferation assay kit, following the 
manufacturer’s instructions. Briefly, 10 μM EdU in a final volume of 0.3 mL 
monolayer medium was added over the coverslip followed by incubation at 37° C for 
16 h. This incubation time was determined by the cell doubling time for NSCs of 
around 20 h (Bose et al., 2010; Sun et al., 2009). Cells were fixed at 48 h post-
MPRED treatment in 4% PFA for 20 min at RT, followed by 2 washes with 3% 
bovine serum albumen (BSA). Cells were permeabilsed by incubation for 20 min in 
0.3% Triton-X 100 in PBS (0.5 mL). Then cells were washed twice in 3% BSA and 
the reagent cocktail for EdU detection was distributed over the cells. Following 
incubation at RT for 30 min (protected from light), the cells were washed twice with 
3% BSA and mounted for fluorescence microscopy. Fluorescence images were 
captured from four random fields of the coverslip. Counts of nuclei co-expressing the 
EdU marker and nuclear counterstain (DAPI) were classified as proliferating cells 
(proliferation expressed as a percentage of the total cells counted). 
 
2.6. Cell cycle analysis 
Cell cycle analysis was performed at 48 h post-MPRED treatment. NSCs (1 x 106) 
were harvested, fixed with 1 ml of 70% cold ethanol and incubated at -20 °C for at 
least 3 h prior to staining, as per the Muse Cell Cycle Kit instructions. Subsequently, 
200 µl of ethanol-fixed cells were washed in PBS and stained for 30 mins at RT in 
the dark with 200 μl of Muse Cell Cycle Reagent. Cell suspensions were transferred 
into 1.5 ml microcentrifuge tubes and analyzed using a Muse Cell Analyzer (EMD 
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Millipore, Darmstadt, Germany), with an automated readout of proportions of cells in 
each phase of the cell cycle. 
 
2.7. Viability assay 
NSC viability was measured at 48 h post-MPRED treatment using LIVE/DEAD 
viability/cytotoxicity kit which contains calcein AM and ethidium homodimer-1 (Ethd-
1). Cells were washed with PBS, incubated for 15 mins with 4 µM calcein AM 
(produces green fluorescence in live cells) and 6 µM Ethd-1(produces red 
fluorescence in dead cells), dissolved in PBS. Cells were then washed again with 
PBS and mounted for fluorescence microscopy. 
2.8. Apoptosis assay 
Muse Annexin V and Dead cell kit was used to quantify apoptotic cells. After 48 h 
treatment of NSCs with MPRED, they were stained with Annexin V, following the 
manufacturer’s instructions. 100 µl of cells in suspension were added to 100 µl of the 
Muse Annexin V and Dead cell reagent and stained for 20 mins at RT in the dark. 
Stained cells were measured by the Muse Cell analyzer.  
 
2.9. NSC differentiation assay 
To examine the effect of MPRED treatment on NSC differentiation, NSCs treated as 
in Section 2.4 were switched to differentiation medium [neurosphere medium without 
growth factors but with addition of 1% fetal bovine serum (FBS)] containing the same 
concentrations of MPRED. Cells were cultured for a further 7 days to allow 
differentiation. At the end of the total incubation time (9 days) cells were fixed with 
4% PFA. 
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2.10. Immunocytochemistry 
Following fixation, non-specific staining was blocked (blocking solution: 5% normal 
donkey serum, 0.3% Triton-X-100 in PBS) for 30 mins at RT. Primary antibodies 
were diluted as follows in blocking solution: Nestin 1:200, H300 1:100, BuGR2 1:100, 
β-tubulin III/TUJ-1 1:1000, GFAP 1:500, MBP 1:200, GAP 43 1:500, added to the 
cells and incubated overnight at 4°C. Stained cells were washed three times in PBS, 
blocked for 30 mins at RT and incubated with the appropriate FITC- or Cy3-
conjugated secondary antibody in blocking solution (1:200 dilution, RT; 2 h), cells 
were then washed three times with PBS at RT, and mounted with DAPI. 
 
2.11. Microscopy and image analysis 
Fluorescence images were taken using an Axio Scope A1 microscope equipped with 
an Axio Cam ICc1 digital camera and AxioVision software (release 4.7.1, Carl Zeiss 
MicroImaging GmbH, Goettingen, Germany). Photoshop CS3 (Adobe, USA) was 
used to merge counterpart images; three channels were merged to form 'triple 
merge’ images. At least four microscopic fields were captured per condition for 
subsequent analysis. The proportions of total numbers of cells expressing a specific 
neural cell markers was expressed versus total cell number estimated using DAPI 
nuclear staining, using ImageJ software. ImageJ software was also used to measure 
the lengths of the axon of neurons and the area occupied by oligodendrocytes. To 
validate proteomic findings regarding GAP 43 expression, fluorescence micrographs 
of control and CS-treated NSCs and their differentiated cells were converted to 
grayscale (Photoshop) and calibrated as a batch (optical density step-tablet, 
Rodbard equation; ImageJ, National Institutes of Health, USA). The relative 
expression of GAP 43 protein was quantified using optical density measurements of 
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individual cells (minimum of 30 nestin+ NSCs and TUJ 1+ neurons and four images 
per condition per culture), with background readings subtracted. 
 
2.12. Statistical analysis of histological data  
All data from the effects of MPRED on the NSC parent cells and their differentiated 
cells were analyzed using Prism statistical analysis software (GraphPad) and are 
presented as mean ± standard error of the mean (SEM). P < 0.05 was chosen as the 
level of statistical significance. Data were analyzed by one-way ANOVA with 
Bonferroni’s multiple comparison tests (MCT) as appropriate. Optical density 
measurements of GAP 43 expression were compared using an unpaired t test. The 
numbers of experiments (n) relate to the number of NSC cultures, each generated 
from a different litter.  
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2.13. Proteomic and bioinformatics analyses 
Proteomic analysis was performed to examine protein expression in NSCs; NSCs 
were plated as monolayers in 6 well plates at 1.2 x 105 cells/ml in 1.5 ml. These were 
left for one day to adhere and then treated with 10 µM MPRED for 48 h. In order to 
obtain protein from the NSCs, the cells were enzymatically detached using TrypLE 
(RT, <5 mins). Cells were pelleted by centrifugation and washed three times in 50 
mM Ammonium Bicarbonate (Ambic) with centrifugation in between each wash. Cell 
pellets were dissolved in 100 µl lysis buffer (0.1% Rapigest, 1% DNAse I in 50mM 
Ambic), and cells were lysed using probe sonication. Cell debris was pelleted at 
15,000 g for 5 mins and the protein concentration of the supernatant fraction of each 
lysate determined by Bradford assay according to manufacturer’s protocol.  
 
2.13.1. Tryptic digestion of cell lysate proteins 
100 µg of each lysate was subjected to in-solution tryptic digestion. Each lysate was 
incubated with 10 mM dithiothreitol with shaking (80°C, 15 mins) before reduction 
using iodoacetamide (20 mM, 30 mins, RT, kept dark). Trypsin (2 µg) was then 
added to each sample, with incubation at 37°C for 16 h. Remaining tryptic activity 
was terminated, and Rapigest precipitated, by addition of trifluoroacetic acid (1% v/v) 
and acetonitrile (2% v/v) with shaking (60°C, 2 h). Rapigest was pelleted and 
removed by centrifugation at 15,000 g for 5 mins, with the supernatant being used 
for mass spectrometry. 
 
2.13.2 Mass spectrometry 
We performed data-independent high-definition MSE analysis (Rodriguez-Suarez et 
al., 2013), with ion mobility separation of precursor and mixed pseudo-product ion 
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data using a Synapt G2Si instrument with associated NanoAcquity UPLC (Waters 
Corporation, Wilmslow, Cheshire) (Ansari et al., 2015; Burniston et al., 2014). Data 
were analysed using Progenesis QI for proteomics (Non-Linear Dynamics, 
Newcastle upon Tyne), with a High-N (n=3) quantification being used to generate 
quantification data (Silva et al., 2005). An ANOVA p value of 0.05 was used as a cut-
off for significance of differential protein identifications. Pathway analysis to identify 
differentially-regulated proteins was performed using Ingenuity Pathway Analysis 
(IPA; QIAGEN, Redwood City CA, www.qiagen.com/ingenuity). Statistical 
enrichment is calculated by a right-tailed Fisher’s exact test. 
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3. Results 
3.1. GR expression in NSCs and their daughter cells 
The parent NSC cultures routinely established in our experiments were of high 
purity: 97.7 (± 1.6) % nestin+ NSCs. After differentiation, daughter cells were 
produced in the following proportions, judged by immunostaining for cell-specific 
markers [84.7 (± 2.1) % GFAP+ astrocytes, 9.2 (± 0.2) % TUJ 1+ neurons and 5.5 (± 
0.2) % MBP+ oligodendrocytes]. In our hands these are the expected ratios using the 
differentiation protocol described. Immunostaining showed positive staining for GR in 
all the cell types in control cultures (Fig. 1A, C, E and G). 10 μM MPRED treatments 
induced nuclear translocation of GR, with greater intensity of nuclear staining 
observed following drug application (Fig. 1B, D, F and H). 
 
 
Fig. 1. NSCs and their daughter cells express GR. Representative fluorescence 
micrographs showing GR expression in untreated cells (A, C, E and G): nestin+ 
NSCs (A), GFAP+ astrocytes (C), TUJ 1+ neurons (E) and MBP+ oligodendrocytes 
(G), compared with MPRED-treated cells (48 h MPRED, 10 μM, panels B, D, F and 
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H): nestin+ NSCs (B) GFAP+ astrocytes (D), TUJ 1+ neurons (F) and MBP+ 
oligodendrocytes (H), n=3. 
 
3.2. Effect of MPRED on the number, proportion and proliferation of NSCs  
Immunostaining for nestin revealed that 10 μM MPRED significantly reduced the 
total counts of NSCs compared with control and vehicle (Fig. 2A, B and C). No 
differences in proportions of nestin positive cells were observed between control 
versus treatment conditions (Fig. 2D). 10 μM MPRED also significantly decreased 
the percentage of Edu+ (proliferative) cells (Fig. 2E, F and G). Cell cycle analysis 
showed that in parallel with reduced proliferation, 10 μM MPRED led to a significant 
increase of cells in the G0/G1 phase with a parallel decrease of cells in S and G2/M 
phases, compared with controls (Fig. 2H).  
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Fig. 2. Effect of MPRED on the number, proportion and proliferation of NSCs. 
Fluorescence images showing nestin positive NSCs in untreated (A) and 10 μM 
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MPRED treated NSCs (B). (C) Bar chart displaying the total number of NSCs per 
field across treatment conditions. (D) Bar chart showing the proportions of nestin 
positive NSC across treatment conditions. Triple merged fluorescence images 
depicting Edu positive NSCs in untreated (E) and 10 μM MPRED treated NSCs (F), 
an asterisk denotes double-labelled cells; arrowhead indicates NSCs that did not 
express Edu marker. (G) Bar chart showing proportions of Edu incorporating cells 
across treatment conditions. (H) Bar chart representing the percentage of the cells in 
the G0/G1, S and G2/M phase of the cell cycle. (48 h MPRED; 0.1 μM, 1 μM and 10 
μM); **p<0.01 versus untreated NSCs; one-way ANOVA, Bonferroni’s post-test; n = 
6 for number and proportion of NSCs and n=3 for Edu assay and cell cycle analysis.  
 
3.3. Effects of MPRED on NSC viability and apoptosis  
LIVE/DEAD staining revealed high cellular viability after MPRED treatment at all 
doses, comparable to control culture viability (Fig. 3A, B and C). Apoptosis of NSCs 
remained low (ca. 4%) across all conditions (Fig. 3D).  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
19 
 
 
Fig. 3. Effect of MPRED on the viability and apoptosis of NSCs. Representative 
LIVE/DEAD fluorescence images of untreated (A) and 10 μM MPRED treated (B) 
NSCs 48 h after treatment. LIVE cells appear green and DEAD cells appear red 
(arrows). (C) Bar chart showing the proportion of viable cells. (D) Bar chart 
displaying the percentage of apoptotic cells. (48 h MPRED; 0.1 μM, 1 μM and 10 
μM); no significance; one-way ANOVA, Bonferroni’s post-test; n = 3. 
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3.4. Effect of MPRED treatment on newly generated daughter cells of NSCs 
Fluorescence micrographs of astrocytes showed similar staining 
profiles/morphologies in all cultures, suggesting no significant MPRED-based effects 
(Fig. 4A and B). There was no significant difference in numbers of daughter 
astrocytes per field across all treatment groups (Fig. 4C). In contrast to astrocytes, 
10 μM MPRED-treated NSCs produced significantly fewer neurons per field versus 
controls (Fig. 4D-G). 10 μM MPRED treatments also resulted in a significant 
reduction in axonal length versus untreated cells [28.9 ± 2.1 μm versus 49.9 ± 4.2 
μm respectively (Fig. 4H)]. However, there was no difference in the number of 
oligodendrocytes generated per field after MPRED treatment. Microscopic 
observations suggested that oligodendrocytes in 10 μM MPRED-treated cultures had 
a greater membrane surface area (Fig. 4I-K). This was confirmed by the total cell 
area measurements wherein control cells and vehicle showed less maturation of 
oligodendrocytes (average area measurement 1418 ± 84.1 μm2 ), while 10 μM 
MPRED-treated cells accelerated the maturation profile of oligodendrocytes 
(average area measurement 1909 ± 68.4 μm2 ) (Fig. 4L).  
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Fig. 4. Effects of MPRED treatment on newly generated daughter cells of NSCs. 
Representative fluorescence micrographs depicting astrocytes generated from 
untreated (A) and 10 μM MPRED treated (B) differentiated NSCs. (C) Bar chart 
displaying the total number of GFAP+ cells per field. Fluorescence micrographs of 
neurons derived from untreated (D) and 10 μM MPRED treated (E) differentiated 
NSCs. (F) Bar chart quantifying the number of TUJ 1+ neurons per field across 
treatment conditions. (G) Bar chart showing the proportion of neurons across 
treatment conditions. (H) Bar chart showing the axonal length of neurons across 
conditions. Note reduced neuronal numbers and axonal lengths in 10 μM MPRED 
treated NSCs compared with untreated. Fluorescence micrographs of 
oligodendrocytes generated from untreated (I) and 10 μM MPRED treated (J) 
differentiated NSCs. Note the different morphologies and membrane surface areas 
of MBP+ oligodendrocytes in treated cultures. (K) Bar chart showing the number of 
oligodendrocytes per field across treatment conditions. (L) Bar chart showing the 
measurement of oligodendrocyte area across treatment conditions. (9 days MPRED; 
0.1 μM, 1 μM and 10 μM); **p < 0.01 and *p < 0.05 versus untreated; one-way 
ANOVA, Bonferroni’s post-test; n = 6. 
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3.5. Molecular analysis of the effects of MPRED on NSCs 
Proteomic analysis was used in this study to provide an unbiased readout of 
molecular phenotype following MPRED treatment. A total of 3,220 quantifiable 
proteins from >20,000 peptide features were identified across the biological and 
technical replicate analyses. Pathway analysis was used to examine clustering of 
differentially-expressed proteins as nodes within molecular networks (Kalayou et al., 
2016). A number of proteins showed significantly altered expression levels, however 
these were isolated entities within otherwise unaffected pathways; no entire 
pathways showed strong evidence of being significantly dysregulated. Whilst not 
linked in a canonical pathway, we next sought to identify dysregulated proteins that 
are known to have direct interaction with corticosteroids. There are 72 corticosteroid 
interacting molecules identified by IPA, 14 of which were proteins identified by the 
proteomics approach used here. Three of these demonstrated significant differential 
expression: down-regulation of matrix metalloproteinase 16 (MMP-16) and growth-
associated protein 43 (GAP-43), and up regulation of cytochrome p450 51 A1 (CYP 
51 A1) (Fig. 5A). Mass spectrometric relative quantification of the peptide features by 
Progenesis QI showed consistent patterns of regulation for the aforementioned 
corticosteroid primary interactors (Fig. 5B). Our results from proteomic analysis were 
confirmed using immunostaining to detect GAP 43. Both NSC parent cells and their 
differentiated cells expressed GAP 43 in treated and untreated cells. However, a 
significant reduction in GAP 43 expression was evident in MPRED treated NSCs and 
in the neurons derived from treated NSCs compared to controls. Quantification of the 
fluorescence intensity of GAP 43 immunostaining revealed that MPRED treated 
NSCs and neurons consistently demonstrated significantly lower optical density 
values than controls (Fig. 6).  
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Fig. 5. Differential protein expression by NSCs following MPRED treatment. (A) 
IngenuityTM Pathway Analysis was used to cluster identified proteins according to 
biochemical pathways differentiating controls from MPRED-treated cells. Nodes in 
red indicate up-regulated proteins while those in green represent down-regulated 
proteins (ANOVA p<0.05, min. 2 fold). Grey nodes indicated protein detection 
without differential expression above the statistical threshold. (B) Progenesis QI for 
proteomics normalised expression profiles of GAP 43, MMP-16 and CYP51A1 
illustrating protein abundance in MPRED-treated cells compared with controls, n=3. 
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Fig. 6. NSCs and their differentiated cells show a reduction in GAP 43 
expression following MPRED treatment. Fluorescence micrographs showing GAP 
43 expression in vehicle control (A) and 10 μM MPRED treated NSCs (B). Note the 
marked reduction in GAP 43 expression following MPRED addition. (A and B insets 
are the same fields with addition of nestin). (C) Bar graph showing the optical density 
measurements of GAP 43 expression in MPRED treated NSCs over vehicle controls. 
(D) Representative fluorescence micrograph of a neuron derived from untreated 
NSCs showing extensive GAP 43 expression. (E) Fluorescent counterpart to D 
showing co-localisation of GAP 43 staining with TUJ 1. (F) Representative 
fluorescence micrograph of neurons derived from 10 μM MPRED treated NSCs 
showing marked reduction in GAP 43 expression. (G) Fluorescent counterpart to F 
with the addition of TUJ 1. (H) Bar graph showing the optical density measurements 
of GAP 43 expression in MPRED of neurons derived from treated NSCs culture over 
vehicle controls. (48 h; 10 μM; unpaired t test; *p < 0.05, n = 3). 
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4. Discussion 
We have carried out dual histological and proteomic analyses to provide an insight 
into the molecular changes induced by CS in NSCs. The use of our dual approach to 
sample cellular proteins in parallel with histological observation of cells in culture 
provides an unbiased survey, unhindered by prior expectation. The observed 
concentration of a tryptic peptide, used as an analytical proxy for the net product of 
protein synthesis and turnover, is poorly predicted by either genome analysis or 
transcript levels (Lawless et al., 2016; Nagaraj et al., 2011). We consider that the 
work provides novel evidence to generate a key starting point to understanding the 
molecular mechanisms by which CSs influence an important neural cell population 
and its differentiated progeny. All cell types were found to express the GR receptor 
and therefore can be considered to be CS-responsive.  
We have used SVZ derived NSCs for these experiments and the use of such cells 
propagated as monolayers is a widely used model in neuroscience research. The 
microanatomy of this region, and roles of SVZ cells in development and pathology 
continue to be elucidated. However, it is well established that this highly specialist 
niche allows for NSCs to survive, and that progenitor/stem cells from this region give 
rise to cells with both neuronal and glial fates. These cells have been shown to play 
repair roles in a range of neonatal animal models including hypoxia-ischemia, stroke, 
congenital cardiac disease and traumatic brain injury (Niimi and Levison, 2017). The 
region is also a major transplant cell source (Zuo et al., 2017) including from adult 
brain biopsies (Aligholi et al., 2016). Accordingly, we consider this to be an 
appropriate model system for the current analyses. In the future, it would be highly 
informative to conduct similar analyses using NSCs derived from a range of sources 
and brain regions.  
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Our study demonstrates that the highest MPRED concentration used induced a 
reduction in NSC number and proliferation. We observed that the percentage of Edu+ 
NSCs was significantly reduced at this concentration. In parallel, cell cycle assay 
results suggest that CS treatment arrests the cell cycle of the NSCs at the G0/G1 
phase. Our findings are broadly in line with previous studies, for example, it was 
demonstrated that MPRED reduced the proliferation of endogenous neural 
precursors (Obermair et al., 2008). Another study shows that MPRED had inhibitory 
effects on precursor proliferation by decreasing the levels of endothelin receptor type 
B protein, involved in regulating the proliferation and apoptosis of endogenous neural 
precursors (Li et al., 2012). Sippel and colleagues also reported that CS treatment of 
NPCs resulted in reduced cell proliferation and expression of a protein called 
BRUCE/Apollon, an apoptosis inhibitor protein family member (Sippel et al., 2009).  
 
These studies were performed using analysis of gene expression and microarray 
analyses, but as far as we are aware, no in-depth study of the influence of CS 
treatment upon protein expression has yet been performed in NSCs. This is 
important as the correlation between transcript and protein expression changes is 
relatively poor, for example only 40% of altered protein expression can be directly 
predicted by changes in transcript levels (Vogel and Marcotte, 2013). We therefore 
consider our proteomic analyses beneficial in this regard, as it enables unbiased 
detection of molecular mechanisms potentially mediating our observed MPRED 
effects on NSC proliferation and differentiation. Follow up hypothesis-driven 
investigations can then be performed on specific identified dysregulated proteins and 
their phenotypic influence; these will be the goal of future research. 
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In line with the current findings, CSs have been found to induce a reduction in 
neurogenesis, axonal length and oligogenesis (Bose et al., 2010; Chetty et al., 2014; 
Kim et al., 2004). Recent experimental studies indicate that CS induced changes in 
neurogenesis are implicated in the regulation of cognition, mood, depression and 
emotional dysfunction (Saxe et al., 2006; Snyder et al., 2012). Our data suggest that 
a potential mechanism underpinning these effects could be via an early cellular re-
programming of the treated parent NSCs, which in turn results in reduced GAP 43 
levels – a nervous tissue–specific protein highly expressed in neurons and glial cells. 
The failure of expression of GAP-43 in NSCs can reduce neurogenesis, increase 
apoptosis of neurons and affect their maturation (Shen et al., 2004). We consider 
this is an important finding impacting neural development, and hence chose GAP-43 
expression for further detailed immunohistochemical analysis. This corroborated 
proteomic data with GAP-43 in both NSCs and newly generated neurons reduced. 
The synthesis of GAP-43 is correlated with the development and regeneration of 
neurons (Hoffman, 1989), therefore GAP-43 down regulation could explain the 
reduced neuronal number and axonal growth in our histological analyses.  
Additionally, MPRED reduced levels of MMP-16, a member of a family of 
proteinases which regulate biological functions such as neurogenesis, axonal 
extension, differentiation and cell migration in the developing and adult nervous 
systems. MMPs play an essential role by extracellular matrix (ECM) remodeling 
(Stamenkovic, 2003); the ECM and its remodeling regulate many aspects of cellular 
behavior such as proliferation, migration and differentiation of neural cells and NSCs 
(Faissner et al., 2010; Fujioka et al., 2012). The involvement of MMPs in ECM 
remodeling enabling axonal extension and repair after brain injury suggests a 
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contribution to the effects on neurogenesis and growth observed in our study; 
specifically, overexpression of MMPs has been shown previously to increase neurite 
extension and migration of neurons during neuronal development (Larsen et al., 
2003; Reeves et al., 2003; Reichardt, 1991). It is not currently clear if the reduction in 
axonal outgrowth represents a maturation delay or a permanent alteration in 
neuronal morphology. In either scenario, the consequences can be predicted to be 
significant. This could pertain to both the establishment and maturation of 
appropriate neuronal circuitry during brain development, but also to processes 
involving complex and timed interactions with other cell types, such as 
oligodendrocytes during the myelination process.  
MPRED treatment did not affect the proportion of NSCs differentiating into astrocytes 
or oligodendrocytes. In contrast, Sabolek et al. observed that CS exposure leads to a 
reduction in astrocyte differentiation (Sabolek et al., 2006). We suggest that the 
observed differences may be attributable to the differences in both methodology and 
origin of NSCs between the two studies. However, MPRED was found to accelerate 
the maturation of newly generated oligodendrocytes, a finding with potential 
implications for the myelination process. Jenkins et al. studied direct actions of CS 
on oligodendrocytes and their progenitors, the oligodendrocyte precursor cells 
(OPCs) in culture. No effects were found on OPC proliferation and survival, or 
oligodendrocyte maturation (Jenkins et al., 2014). However, we suggest that the 
known CS effects on myelin genesis (Chari et al., 2006; Clarner et al., 2011) may 
alternatively be mediated via changes in the interactions of newly generated 
oligodendrocytes with axons in the developing nervous system; this is normally a 
highly spatially and temporally controlled process. Premature maturation of 
oligodendrocytes can be predicted to result in aberrant myelination. Our findings 
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suggest a possible link between the upregulation of key protein involved in 
cholesterol biosynthesis, CYP51A1 (aka lanosterol 14 α-demethylase) and the 
maturation of oligodendrocytes. CYP51A1 is involved in important steps in the 
biosynthesis of cholesterol (Björkhem et al., 2004; Debeljak et al., 2003) which is 
which is found in high levels in myelin, (Orth and Bellosta, 2012). We therefore 
suggest that alterations in cholesterol biosynthesis could be associated with 
impairments to oligodendrocyte development and the myelination process.  
In ongoing work, our laboratory has tested two more clinically relevant and widely 
used CSs - dexamethasone and prednisone in identical studies. Overall, a similar 
profile was observed across all three preparations, suggesting the need for careful 
evaluation of the effects of this major class of drugs on development and fate of 
NSCs. 
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5. Conclusion 
In summary, our analyses suggest that the down regulation of major neural 
development proteins MMP-16 and GAP-43, along with MPRED induced 
upregulation of CYP51A1 proteins involved in cholesterol synthesis, provides an 
explanation for the observed histological effects of MPRED on NSCs. The clustering 
of these proteins within a single network suggests MPRED treatment acts by altering 
a common upstream regulator of these proteins, rather than individual disparate 
nodes being affected in unrelated molecular pathways. Detailed analysis of the 
relative contributions of the multiple competing cellular processes (transcriptional, 
co-transcriptional, translational, post-translational or protein degradation) which 
result in net protein concentration is beyond the scope of the current study, but this 
finding suggests opportunities for further investigation of MPRED influence on NSCs. 
Our findings highlight the need for development of new immunosuppressive agents 
and treatment regimens to reduce adverse neurological effects of CSs on stem cell 
populations of the nervous system. 
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Highlights: 
 Treatment of NSCs with a widely used clinical corticosteroid showed that proliferation of 
neural stem cells was reduced by the treatment. 
  Genesis of neurons and axonal length were reduced, while oligodendrocyte maturation was 
increased after corticosteroids treatment. 
 First investigation into underlying mechanisms by proteomic analysis showed corticosteroid 
induced downregulation of growth associated protein 43 and matrix metallopeptidase 16 
with upregulation of the cytochrome P450 family 51 subfamily A member 1 
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